<DOC>
	<DOCNO>NCT01215253</DOCNO>
	<brief_summary>The purpose study see effective drug call ranolazine reduce risk ventricular arrhythmia death people implantable cardioverter-defibrillators ( ICDs ) . This drug use standard medication routinely prescribe enrolled patient .</brief_summary>
	<brief_title>Ranolazine Implantable Cardioverter-Defibrillator Trial</brief_title>
	<detailed_description>There limited treatment option patient high risk ventricular arrhythmic event . Beta-blockers alone provide enough protection , sotalol limit effectiveness , amiodarone although effective group patient use infrequently due side effect limitation long-term use . Ischemia cardiomyopathy associate sodium overload myocardial cell . Late sodium current play pivotal role process . Sodium overload lead calcium overload myocardial cell consequent increase vulnerability myocardium ventricular tachyarrhythmias well increase impairment diastolic relaxation myocardium thereby augment risk ischemia myocardial damage . Ranolazine novel drug anti-ischemic antiarrhythmic property uniquely block late sodium current , decrease intracellular calcium overload , improve diastolic relaxation ventricle . The antiischemic antiarrhythmic property ranolazine might decrease likelihood arrhythmic event improve clinical course patient ventricular arrhythmia . We design randomize double-blind placebo-controlled clinical trial enrol 1,440 high-risk ICD patient treat ranolazine placebo addition optimal medical therapy test hypothesis late sodium current blockade contributes significant reduction risk arrhythmic event death high-risk ICD/CRT-D patient .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<criteria>1,440 highrisk patient ischemic/nonischemic cardiomyopathy receive ICDs standard care primary secondary prevention mortality follow approve indication ICD therapy . Highrisk patient define : Secondary Prevention Patients Subjects ischemic nonischemic cardiomyopathy , qualify exist ICD ( CRTD ) document VT/VF cardiac arrest ( secondary prevention mortality ) . Secondary prevention subject exist implant eligible regardless implant receive ( subject could recruit outpatient clinic inpatient activity include reimplant procedure ) . Primary Prevention Patients 1 . Patients primary prevention indication ischemic nonischemic cardiomyopathy EF≤35 % , exist device ( ICD/CRTD ) , regardless device implant , experience least ONE episode VT/VF appropriately treat ICD therapy ( ATP shock ) untreated NSVT last least 10 beat heart rate least 170 bpm , document electrogram implant device . 2 . Patients ischemic nonischemic cardiomyopathy EF≤35 % , implant within last 2 year ( initial ICD/CRTD implant , include upgrades pacemaker ) NOT experience VT/VF treat ICD therapy ( ATP shock ) , AND ONE follow additional criterion : BUN≥26 mg/dl QRS &gt; 120ms Atrial Fibrillation NSVT document ECG/Holter &gt; 500 Ventricular Premature Beats ( VPBs ) document 24hour Holter . Stable optimal pharmacologic therapy cardiac condition Age : equal 21 year without upper limit Patient receive first device coronary artery bypass graft surgery within last 3 calendar month prior date consent obtain Patients receive first device percutaneous coronary intervention within last 1 calendar month prior date consent obtain Patient receive first device enzymepositive myocardial infarction past 3 calendar month prior date consent obtain Patient receive first device angiographic evidence coronary disease candidate coronary revascularization likely undergo coronary artery bypass graft surgery percutaneous coronary intervention foreseeable future Patient NYHA Class IV Patients receive prophylactic ablation ventricular substrate Patients preexist QTc prolongation &gt; 550ms Patients strong CYP3A inhibitor ( include ketoconazole , itraconazole , clarithromycin , nefazodone , nelfinavir , ritonavir , indinavir saquinavir moderate CYP3A inhibitor , include , diltiazem , verapamil , aprepitant , erythromycin , fluconazole grapefruit juice grapefruitcontaining product . Patients CYP3A inducer rifampin , rifabutin , rifapentine , phenobarbital , phenytoin , carbamazepine St.John 's wort Patients inherited arrhythmia disorder Brugada 's , ARVD , LQTS hypertrophic cardiomyopathy Patient pregnant plan become pregnant course trial ( patient child bear age use prescribe pharmaceutical contraceptive could enrol ) Patient irreversible brain damage preexist cerebral disease Patient presence disease , patient 's cardiac disease , associate reduce likelihood survival duration trial , e.g. , cancer , uremia , liver failure , etc . Patient chronic renal disease creatinine &gt; 2.5 mg/dl creatinine clearance &lt; 30 ml/min Patient participate clinical trial Patient unwilling unable cooperate protocol Patient live distance clinic travel followup visit would unusually difficult Patient anticipate resident area schedule duration trial Patients decisionally impair adult , questionable capacity , consent recruit study . Patient unwilling sign consent participation</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Sudden Death</keyword>
	<keyword>Ranolazine</keyword>
	<keyword>Heart failure</keyword>
	<keyword>Ventricular tachycardia</keyword>
	<keyword>Ventricular fibrillation</keyword>
	<keyword>Implantable cardioverter-defibrillator</keyword>
</DOC>